You don’t have permission to access “http://www.medpagetoday.com/publichealthpolicy/publichealth/116124” on this server. Reference #18.94c1c917.1750212373.104eb992 https://errors.edgesuite.net/18.94c1c917.1750212373.104eb992 Read MoreContinue Reading
(Reuters) -Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday. With the addition of the 12.5 milligrams and 15 mg doses, all approved doses of Zepbound will be available onContinue Reading
Please complete security verification This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation! Press and hold the button If you believe this is an error, please contact our supportContinue Reading
TOPLINE: Direct immunofluorescence (DIF) microscopy showed a 15.5% positivity rate in pediatric patients and changed the clinical diagnosis in 16.7% of those cases. METHODOLOGY: Researchers conducted a retrospective review of DIF data from 986 patients aged 0-18 years (mean age, 12 years) at the Mayo Clinic’s reference immunodermatology laboratory betweenContinue Reading
Credit: Wellness Gallery Catalyst Foundation from Pexels If you were to ask most people what causes cancer, the answer would probably be smoking, alcohol, the sun, hair dye or some other avoidable element. But the most important risk factor for cancer is something else: aging. That’s right, the factor mostContinue Reading
Please complete security verification This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation! Press and hold the button If you believe this is an error, please contact our supportContinue Reading
Please complete security verification This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation! Press and hold the button If you believe this is an error, please contact our supportContinue Reading
VIENNA — The use of expanded-criteria donors for kidney transplantation in older and high-risk recipients did not provide the same survival benefit as the use of standard donors, according to an analysis of data from more than 64,000 individuals in the European Renal Association (ERA) Registry, using target trial emulation. Continue Reading
The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for disease progression or death by more than the current standard-of-care treatment. Sara Tolaney, MD, MPH Sara Tolaney, MD, MPH, of the Dana-Farber CancerContinue Reading
TOPLINE: Interleukin (IL)-23p19 inhibitors guselkumab and risankizumab demonstrated the highest drug survival for effectiveness and safety comparable with ustekinumab over 2 years, exceeding that of all other biologics. IL-17 receptor inhibitor brodalumab showed comparable effectiveness and safety with adalimumab and secukinumab. METHODOLOGY: Researchers conducted a cohort study using data fromContinue Reading
Skip to content